[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555831":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":43,"centralContacts":44,"locations":50,"responsibleParty":89,"collaborators":43,"id":91,"slug":43,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":43,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":98,"maxAge":43,"enrollmentInfo":99,"targetDuration":43,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":53,"whyStopped":43,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Mahidol University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"placebo","PLACEBO_COMPARATOR","placebo 1 tablet\u002Fday for 28 days",[13],"Drug: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"olanzapine 2.5","ACTIVE_COMPARATOR","olanzapine 2.5 mg\u002Fday for 28 days",[19],"Drug: Olanzapine 2.5 MG",{"label":21,"type":16,"description":22,"interventionNames":23},"olanzapine 5","olanzapine 5 mg\u002Fday for 28 days",[24],"Drug: Olanzapine 5 MG",[26,32,37],{"type":27,"name":28,"description":17,"armGroupLabels":29,"otherNames":30},"DRUG","Olanzapine 2.5 MG",[15],[31],"OLN2.5",{"type":27,"name":33,"description":22,"armGroupLabels":34,"otherNames":35},"Olanzapine 5 MG",[21],[36],"OLN5",{"type":27,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Placebo","placebo 1 tab\u002Fday for 28 days",[9],[42],"PLC",null,[45],{"name":46,"role":47,"phone":48,"phoneExt":43,"email":49},"Suthinee Ithimakin, MD","CONTACT","+66824194489","aesi105@yahoo.co.th",[51,67],{"facility":52,"status":53,"city":54,"state":43,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Faculty of Medicine Siriraj Hospital","RECRUITING","Bangkok","10260","Thailand",{"type":58,"coordinates":59},"Point",[60,61],100.50144,13.75398,{"lat":61,"lon":60},[64],{"name":65,"role":47,"phone":66,"phoneExt":43,"email":49},"Suthinee Ithimakin","0898127440",{"facility":68,"status":53,"city":54,"state":43,"zip":69,"country":56,"cosmosGeoPoint":70,"geoPoint":72,"contacts":73},"Division of medical oncology, department of medicine Siriraj Hospital","10700",{"type":58,"coordinates":71},[60,61],{"lat":61,"lon":60},[74,76,78,81,83,85,87],{"name":46,"role":47,"phone":75,"phoneExt":43,"email":49},"662-419-4489",{"name":46,"role":77,"phone":43,"phoneExt":43,"email":43},"PRINCIPAL_INVESTIGATOR",{"name":79,"role":80,"phone":43,"phoneExt":43,"email":43},"Apirom Laocharoenkeat, MS","SUB_INVESTIGATOR",{"name":82,"role":80,"phone":43,"phoneExt":43,"email":43},"Akarin Nimmannit, MD",{"name":84,"role":80,"phone":43,"phoneExt":43,"email":43},"Ruamporn Kaewvichit, MD",{"name":86,"role":80,"phone":43,"phoneExt":43,"email":43},"Pinyo Sriveerachai, MD",{"name":88,"role":80,"phone":43,"phoneExt":43,"email":43},"Pornpoj Pramyothin, MD",{"type":90,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100555831",false,"NCT06517199","Olanzapine for Cancer Related Anorexia-cachexia Syndrome","Randomized Placebo-controlled Study of Olanzapine for Cancer Related Anorexia-cachexia Syndrome","Inclusion Criteria:\n\n* pathologically or cytologically metastatic or locally advanced cancer\n* anorexia and \\>=5% weight loss during the past 6 months or anorexia with numerical scale of anorexia \\>=5\n* ECOG performance status 0-3\n* able to complete questionaire and able to swallow pills\n\nExclusion Criteria:\n\n* receiving chemotherapy or anti-cancer systemic therapy\n* life expectancy longer than 1 month\n* received radiotherapy at head\u002Fneck or thoracic or upper abdomen in the past 2 weeks\n* surgery within 4 weeks\n* pregnancy\n* serum bilirubin \\> 2 mg\u002Fdl or serum Cr \\> 2 mg\u002Fdl\n* current use of olanzapine or other antipsychotic drug\n* known cardiac arrhythmia, uncontrolled brain metastasis, history of seizure or acute coronary event in the past 6 months","ALL","18 Years",{"count":100,"type":101},138,"ESTIMATED","INTERVENTIONAL",[104],"PHASE3","Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.",[107,108],"Anorexia","Cachexia",[110,111],"cancer anorexia","olanzapine","2024-07-18",{"date":114,"type":115},"2024-07-24","ACTUAL",{"date":117,"type":115},"2024-01-22",{"date":119,"type":101},"2026-01-21",{"name":5,"class":6},2]